Reply to Baklouti et al., “Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?”

2021 ◽  
Author(s):  
Pier Giorgio Cojutti ◽  
Matteo Rinaldi ◽  
Eleonora Zamparini ◽  
Nicolò Rossi ◽  
Sara Tedeschi ◽  
...  
Keyword(s):  
Pharmacokinetic Study ◽  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Optimal Treatment ◽  
Adult Patients ◽  
Population Pharmacokinetic ◽  
External Evaluation ◽  
Population Pharmacokinetic Study ◽  
Osteoarticular Infections ◽  
French Group

We thank Baklouti et al. (1) for commenting on our population pharmacokinetic study of dalbavancin for optimal treatment of adult patients with staphylococcal osteoarticular infections (2) and for suggesting that our model tends to underestimate the concentrations observed in a group of French patients (French group).…

scholarly journals Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects

Pharmaceutics ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 754
Author(s):  
Seung-Hyun Jeong ◽  
Ji-Hun Jang ◽  
Hea-Young Cho ◽  
Yong-Bok Lee
Keyword(s):  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Population Pharmacokinetic Analysis ◽  
Pharmacokinetic Analysis ◽  
Pharmacokinetic Parameters ◽  
Population Pharmacokinetic ◽  
Factors Affecting ◽  
Population Pharmacokinetic Study ◽  
Final Population ◽  
Subject Variability

The aims of this study were: (1) to perform population pharmacokinetic analysis of cefaclor in healthy Korean subjects, and (2) to investigate possible effects of various covariates on pharmacokinetic parameters of cefaclor. Although cefaclor belongs to the cephalosporin family antibiotic that has been used in various indications, there have been very few population studies on factors affecting its pharmacokinetics. Therefore, this study is very important in that effective therapy could be possible through a population pharmacokinetic study that explores effective covariates related to cefaclor pharmacokinetic diversity between individuals. Pharmacokinetic results of 48 subjects with physical and biochemical parameters were used for the population pharmacokinetic analysis of cefaclor. A one-compartment with lag-time and first-order absorption/elimination was constructed as a base model and extended to include covariates that could influence between-subject variability. Creatinine clearance and body weight significantly influenced systemic clearance and distribution volume of cefaclor. Cefaclor’s final population pharmacokinetic model was validated and some of the population’s pharmacokinetic diversity could be explained. Herein, we first describe the establishment of a population pharmacokinetic model of cefaclor for healthy Koreans that might be useful for customizing cefaclor or exploring additional covariates in patients.

scholarly journals External Evaluation of a Gentamicin Infant Population Pharmacokinetic Model Using Data from a National Electronic Health Record Database

2018 ◽  
Vol 62 (9) ◽  
Author(s):  
Shufan Ge ◽  
Ryan J. Beechinor ◽  
Christoph P. Hornik ◽  
Joseph F. Standing ◽  
Kanecia Zimmerman ◽  
...  
Keyword(s):  
Electronic Health Record ◽  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Population Pharmacokinetic ◽  
Health Record ◽  
External Evaluation ◽  
Data Source ◽  
Electronic Health ◽  
Using Data ◽  
Neonates And Infants

ABSTRACTGentamicin is a common antibiotic used in neonates and infants. A recently published population pharmacokinetic (PK) model was developed using data from multiple studies, and the objective of our analyses was to evaluate the feasibility of using a national electronic health record (EHR) database for further external evaluation of this model. Our results suggest that, with proper data capture procedures, EHR data can serve as a potential data source for external evaluation of PK models.

scholarly journals Pharmacokinetic study after single oral dose of beta-lactam and fluoroquinolone antimicrobials in Bangladeshi healthy male volunteers

2014 ◽  
Vol 30 (1) ◽  
pp. 16-24
Author(s):  
Reefat Zaman Chowdhury ◽  
Md Saiful Islam ◽  
Md Sayedur Rahman
Keyword(s):  
Pharmacokinetic Study ◽  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Population Pharmacokinetic ◽  
Pharmacokinetic Data ◽  
Healthy Male ◽  
Beta Lactam ◽  
Beta Lactams ◽  
Male Volunteers ◽  
Bangladeshi Population

The variability of response to antimicrobial has been inadequately explained because of lack of pharmacokinetic data. The present pharmacokinetic study was designed to provide information beneficial to formulate a population pharmacokinetic model appropriate for Bangladeshi population. Among the beta-lactams, amoxicillin (500 mg), flucloxacillin (250 mg), cefuroxime (500 mg) and among the fluoroquinolones, ciprofloxacin (500 mg), levofloxacin (500 mg), gatifloxacin (400 mg) were studied in 15 healthy Bangladeshi male volunteers. The Cmax, AUC0–infinity, Tmax, T1/2 and Ctrough were studied with all antimicrobials. Later, the Cmax and AUC0–infinity were adjusted for bodyweight and dose. Among the studied antimicrobials, the Cmax varied to great extent even after adjustment for bodyweight and dose. The Cmax after adjustment was highest in case of flucloxacillin and lowest in case of ciprofloxacin, indicating excellent absorption of flucloxacillin in Bangladeshi population. The information obtained through this study generates necessity of new cut-off value for the antimicrobials.DOI: http://dx.doi.org/10.3329/bjpp.v30i1.20789 Bangladesh J Physiol Pharmacol 2014; 30(1):16-24

Sign in / Sign up

Export Citation Format

Share Document